Super-enhancers (SEs) drive specific gene expression programmes underlying different cancer cell states offering opportunities for therapeutic targeting. Here, the authors suggest targeting SE-dependent genes with synthetic ecteinascidins in tumors with heterogeneous transcriptional landscapes.
- Max Cigrang
- Julian Obid
- Frédéric Coin
